Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs either monotherapy: ValVET primary results

Joseph L. Izzo, Howard S. Weintraub, Daniel A. Duprez, Das Purkayastha, Dion Zappe, Rita Samuel, William Cushman

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

This 16-week trial investigated the efficacy and safety of single-pill valsartan/hydrochlorothiazide (HCTZ) vs the individual components in patients 70years and older with systolic hypertension. Patients were randomized to valsartan/HCTZ 160/12.5mg (n=128), HCTZ 12.5mg (n=128), or valsartan 160mg (n=128) for 4weeks. Patients whose blood pressure (BP) was ≥140/90mmHg at weeks 4, 8, or 12 were up-titrated to a maximum of valsartan/HCTZ 320/25mg. Week 4 systolic BP reduction (primary efficacy outcome) was greater with valsartan/HCTZ than valsartan (-17.3mmHg vs -8.6mmHg, P<.0001) but only marginally greater than HCTZ (-13.6mmHg, P = .096). Median time to BP control was shorter with valsartan/HCTZ (4weeks) vs HCTZ (8weeks, P<.05) or valsartan (12weeks, P<.0001). Thiazide monotherapy was more effective than angiotensin receptor blocker monotherapy (by about 5mmHg), but greater antihypertensive efficacy was achieved by initiating treatment with combination valsartan/HCTZ in the elderly.

Original languageEnglish (US)
Pages (from-to)722-730
Number of pages9
JournalJournal of Clinical Hypertension
Volume13
Issue number10
DOIs
StatePublished - Oct 1 2011

Fingerprint

Valsartan
Hydrochlorothiazide
Hypertension
Blood Pressure
Thiazides
Angiotensin Receptor Antagonists

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this

Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs either monotherapy : ValVET primary results. / Izzo, Joseph L.; Weintraub, Howard S.; Duprez, Daniel A.; Purkayastha, Das; Zappe, Dion; Samuel, Rita; Cushman, William.

In: Journal of Clinical Hypertension, Vol. 13, No. 10, 01.10.2011, p. 722-730.

Research output: Contribution to journalArticle

Izzo, Joseph L. ; Weintraub, Howard S. ; Duprez, Daniel A. ; Purkayastha, Das ; Zappe, Dion ; Samuel, Rita ; Cushman, William. / Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs either monotherapy : ValVET primary results. In: Journal of Clinical Hypertension. 2011 ; Vol. 13, No. 10. pp. 722-730.
@article{c53f12d16a654c27817d23e0ff73af30,
title = "Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs either monotherapy: ValVET primary results",
abstract = "This 16-week trial investigated the efficacy and safety of single-pill valsartan/hydrochlorothiazide (HCTZ) vs the individual components in patients 70years and older with systolic hypertension. Patients were randomized to valsartan/HCTZ 160/12.5mg (n=128), HCTZ 12.5mg (n=128), or valsartan 160mg (n=128) for 4weeks. Patients whose blood pressure (BP) was ≥140/90mmHg at weeks 4, 8, or 12 were up-titrated to a maximum of valsartan/HCTZ 320/25mg. Week 4 systolic BP reduction (primary efficacy outcome) was greater with valsartan/HCTZ than valsartan (-17.3mmHg vs -8.6mmHg, P<.0001) but only marginally greater than HCTZ (-13.6mmHg, P = .096). Median time to BP control was shorter with valsartan/HCTZ (4weeks) vs HCTZ (8weeks, P<.05) or valsartan (12weeks, P<.0001). Thiazide monotherapy was more effective than angiotensin receptor blocker monotherapy (by about 5mmHg), but greater antihypertensive efficacy was achieved by initiating treatment with combination valsartan/HCTZ in the elderly.",
author = "Izzo, {Joseph L.} and Weintraub, {Howard S.} and Duprez, {Daniel A.} and Das Purkayastha and Dion Zappe and Rita Samuel and William Cushman",
year = "2011",
month = "10",
day = "1",
doi = "10.1111/j.1751-7176.2011.00498.x",
language = "English (US)",
volume = "13",
pages = "722--730",
journal = "Journal of Clinical Hypertension",
issn = "1524-6175",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs either monotherapy

T2 - ValVET primary results

AU - Izzo, Joseph L.

AU - Weintraub, Howard S.

AU - Duprez, Daniel A.

AU - Purkayastha, Das

AU - Zappe, Dion

AU - Samuel, Rita

AU - Cushman, William

PY - 2011/10/1

Y1 - 2011/10/1

N2 - This 16-week trial investigated the efficacy and safety of single-pill valsartan/hydrochlorothiazide (HCTZ) vs the individual components in patients 70years and older with systolic hypertension. Patients were randomized to valsartan/HCTZ 160/12.5mg (n=128), HCTZ 12.5mg (n=128), or valsartan 160mg (n=128) for 4weeks. Patients whose blood pressure (BP) was ≥140/90mmHg at weeks 4, 8, or 12 were up-titrated to a maximum of valsartan/HCTZ 320/25mg. Week 4 systolic BP reduction (primary efficacy outcome) was greater with valsartan/HCTZ than valsartan (-17.3mmHg vs -8.6mmHg, P<.0001) but only marginally greater than HCTZ (-13.6mmHg, P = .096). Median time to BP control was shorter with valsartan/HCTZ (4weeks) vs HCTZ (8weeks, P<.05) or valsartan (12weeks, P<.0001). Thiazide monotherapy was more effective than angiotensin receptor blocker monotherapy (by about 5mmHg), but greater antihypertensive efficacy was achieved by initiating treatment with combination valsartan/HCTZ in the elderly.

AB - This 16-week trial investigated the efficacy and safety of single-pill valsartan/hydrochlorothiazide (HCTZ) vs the individual components in patients 70years and older with systolic hypertension. Patients were randomized to valsartan/HCTZ 160/12.5mg (n=128), HCTZ 12.5mg (n=128), or valsartan 160mg (n=128) for 4weeks. Patients whose blood pressure (BP) was ≥140/90mmHg at weeks 4, 8, or 12 were up-titrated to a maximum of valsartan/HCTZ 320/25mg. Week 4 systolic BP reduction (primary efficacy outcome) was greater with valsartan/HCTZ than valsartan (-17.3mmHg vs -8.6mmHg, P<.0001) but only marginally greater than HCTZ (-13.6mmHg, P = .096). Median time to BP control was shorter with valsartan/HCTZ (4weeks) vs HCTZ (8weeks, P<.05) or valsartan (12weeks, P<.0001). Thiazide monotherapy was more effective than angiotensin receptor blocker monotherapy (by about 5mmHg), but greater antihypertensive efficacy was achieved by initiating treatment with combination valsartan/HCTZ in the elderly.

UR - http://www.scopus.com/inward/record.url?scp=80053564778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053564778&partnerID=8YFLogxK

U2 - 10.1111/j.1751-7176.2011.00498.x

DO - 10.1111/j.1751-7176.2011.00498.x

M3 - Article

C2 - 21974759

AN - SCOPUS:80053564778

VL - 13

SP - 722

EP - 730

JO - Journal of Clinical Hypertension

JF - Journal of Clinical Hypertension

SN - 1524-6175

IS - 10

ER -